Simmons Bank Acquires 3,090 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Simmons Bank increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 60.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,224 shares of the medical research company's stock after purchasing an additional 3,090 shares during the period. Simmons Bank's holdings in Thermo Fisher Scientific were worth $5,087,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Beaumont Financial Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 0.8% during the 1st quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company's stock worth $1,278,000 after acquiring an additional 17 shares during the period. Cedar Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 14.5% during the 1st quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company's stock worth $78,000 after acquiring an additional 17 shares during the period. Lafayette Investments Inc. grew its holdings in shares of Thermo Fisher Scientific by 2.1% during the 2nd quarter. Lafayette Investments Inc. now owns 830 shares of the medical research company's stock worth $459,000 after acquiring an additional 17 shares during the period. IFG Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 3.3% during the 3rd quarter. IFG Advisors LLC now owns 532 shares of the medical research company's stock worth $329,000 after acquiring an additional 17 shares during the period. Finally, Patrick M Sweeney & Associates Inc. grew its stake in shares of Thermo Fisher Scientific by 1.8% in the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company's stock worth $570,000 after buying an additional 18 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $1.15 during trading hours on Wednesday, hitting $541.90. The stock had a trading volume of 1,199,686 shares, compared to its average volume of 1,461,568. Thermo Fisher Scientific Inc. has a one year low of $455.22 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The stock's 50-day moving average price is $591.27 and its two-hundred day moving average price is $583.32. The stock has a market capitalization of $207.28 billion, a price-to-earnings ratio of 33.90, a PEG ratio of 3.57 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm's revenue was up .2% on a year-over-year basis. During the same quarter last year, the business posted $5.69 earnings per share. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be given a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.29%. Thermo Fisher Scientific's dividend payout ratio is currently 9.78%.

Analysts Set New Price Targets

TMO has been the topic of several recent research reports. Sanford C. Bernstein cut their price target on Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating on the stock in a research note on Thursday, October 24th. UBS Group raised Thermo Fisher Scientific to a "strong-buy" rating in a research report on Monday, September 16th. Stifel Nicolaus lowered their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. Evercore ISI lowered their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Finally, JPMorgan Chase & Co. increased their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $649.33.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares in the company, valued at approximately $8,076,178.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the transaction, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 9,000 shares of the business's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the sale, the chief executive officer now owns 14,608 shares of the company's stock, valued at $8,076,178.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,150 shares of company stock worth $20,651,865. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.